FibroBiologics Says USPTO Issues US Patent Entitled Methods And Compositions For Treatment Of Type 1 Diabetes Using Fibroblasts In Facilitation Of Islet Engraftment
Patent has potential for applications beyond diabetes, including other cell and tissue transplantation proceduresHOUSTON, Aug. 11, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a
FibroBiologics received official government permission to use their fibroblast technology for treating type 1 diabetes and potentially other transplant treatments. This is a legal win that shows their science works, giving the company more ways to help patients and grow their business.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.